AR-CHOP-21
Rekrutierung gestartet
A Phase 3, Randomizes, Double-Blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Acalabrutinib plus R-CHOP Versus Placebo plus R-CHOP in Adult Participants e 65 Years with Preiously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Acalabrutinib + R-CHOP vs R-CHOP
Rekrutierungsziel erreicht/keine neuen Patienten
Frau Dr. med. Philine Ahrdorf
philine.ahrdorf@astrazeneca.com
AstraZeneca GmbH (Unternehmen, 12264)
Tinsdaler Weg 183
22880 Wedel
PFS (AR-CHOP vs R-CHOP)
EFS, BICR PET-CT rate, OS, Safety, PF
1L DLBCL, 18-65y, measurable disease, ECOG d 2, R-IPI e 2
N=600, HR 0,67, power 84%, alpha 0,05
PFS (AR-CHOP vs R-CHOP)
EFS, BICR PET-CT rate, OS, Safety, PF
s. Dokument anbei
s. Dokument anbei
Behandlung: 8 Zyklen
Treatment Disease FU: 5 y
Survival FU
D: 10-12
AstraZeneca
?
Ja